Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30297030 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL29049144 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL11147865 | 1.00 | LMNA (0.46) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL8149852 | 0.85 | LMNA (0.36) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL11148565 | 0.85 | LMNA (0.36) | LMNAL3MBTL1TDP1KDM4E | |
| SCHEMBL27663277 | 0.84 | LMNA (0.43) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL8041033 | 0.80 | LMNA (0.50) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| SCHEMBL14028803 | 0.79 | TSHR (0.32) | TDP1 | |
| SCHEMBL4941874 | 0.79 | TSHR (0.32) | TDP1 | |
| SCHEMBL8024173 | 0.79 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119384269-A | Methods of treating ocular disorders using lipid binding protein-based complexes | 阿比奥尼克斯制药公司 | 2025-01-28 | — | — | CN | claimed |
| CN-117018220-A | Preparation of solid cyclodextrin complexes for delivery of an ophthalmically active pharmaceutical ingredient | 奥库里斯经营管理有限责任公司 | 2023-11-10 | — | — | CN | claimed |
| CN-116322646-A | Compositions comprising lipid binding protein-based complexes for the treatment of ocular diseases | 阿比奥尼克斯制药公司 | 2023-06-23 | — | — | CN | claimed |
| CN-119384269-A | Methods of treating ocular disorders using lipid binding protein-based complexes | 阿比奥尼克斯制药公司 | 2025-01-28 | — | — | CN | disclosed |
| CN-117018220-A | Preparation of solid cyclodextrin complexes for delivery of an ophthalmically active pharmaceutical ingredient | 奥库里斯经营管理有限责任公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-110177576-B | Preparation of solid cyclodextrin complexes for delivery of an ophthalmically active pharmaceutical ingredient | 奥库里斯公司 | 2023-08-11 | — | — | CN | disclosed |
| CN-116322646-A | Compositions comprising lipid binding protein-based complexes for the treatment of ocular diseases | 阿比奥尼克斯制药公司 | 2023-06-23 | — | — | CN | disclosed |